Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Mentor Foster Care Celebrates National Adoption Month this November

Sevita

MENTOR Foster Care, a provider of foster care services and part of the Sevita family, is celebrating National Adoption Month this November. National Adoption Month serves as a reminder of the bonds that form through adoption and the importance of providing children with loving, forever homes. The month honors the significance of family and the diversity of families and the paths which bring them together. It also raises awareness of the many children in need and encourages prospective families to learn more. Currently, there are over 390,000 children in foster care. Of those, the average age is around eight years old. However, children come from many different age groups and can be anywhere from infants to young adults up to 20 years old. They also come from many different backgrounds, situations, and needs and deserve a loving and caring home. Oftentimes, foster care becomes the pathway to permanent adoption, known as foster care adoption. Foster care adoption differs from the temporary foster care system — it represents a stable, reliable placement for children and teens in care and provides them with long-term support when reunification with parents is not an option. Fostering and adoption make long-term positive impacts when children are placed in a safe, loving home. For kids, benefits include trust building, educational support and growth, increased social and emotional skills, more positive longer-term outcomes, and more. Additional information on the benefits of foster care can be found here. The number of children adopted from foster care in FY 2021 was 54,240, a 6% decrease from the year prior (FY 2020) and over an 18% decrease from FY 2019. Additional foster families are needed as many children await their forever homes. Sevita’s Mentor Foster Care programs help foster parents provide an environment where children can thrive. Interested individuals can find a complete guide to becoming a foster parent and how Sevita can support you through the journey here. This National Adoption Month, Sevita and its Mentor Foster Care programs celebrate all foster families supporting children across the country and hopes to inspire others to join in its effort to support the youth who need it most. And for those who have adopted children, through foster care or elsewhere, Sevita shares seven ways to celebrate this month. ### MENTOR Foster Care is part of the Sevita family and has been a trusted provider of foster care services since 1980, when it first began offering services as Massachusetts MENTOR. Today, Mentor Foster Care supports thousands of youth and families in nine U.S. states. Our unique model of foster care places children in loving homes with foster parents who support their healing and growth. Services are tailored to each child’s needs and may include trauma-focused counseling services, family and community activities, case management, life skill building, and skill development and support for foster parents. With the support of a clinical team, case managers, and other supportive staff, foster parents help youth with a wide range of challenges heal after trauma and set a hopeful path for their lives. Learn more at sevita.us/foster. Sevita is a leading provider of community-based specialized health care, inspired by our core values of respect, integrity, inclusion and growth. We provide people with quality services and individualized supports that lead to growth and independence, despite the physical, intellectual, or behavioral challenges they face. We’ve made this our mission for more than 50 years. Today our team members continue to innovate and enhance care for the 50,000+ individuals we serve. sevitahealth.com Contact Details Melissa Patricio media@sevitahealth.com Company Website https://sevitahealth.com/

November 21, 2023 01:00 PM Eastern Standard Time

News Release

Valeo Pharma announces new chief financial officer along with $2 million in cost reductions

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share details about recent executive changes within the company. Saviuk announced the appointment of Pascal Tougas as the new chief financial officer, succeeding Luc Mainville. Tougas is recognized as a well-experienced senior executive in the pharmaceutical industry, with a robust financial background. His previous tenure at Sanofi Canada for 11 years saw him in various key roles, including Country Head, Trade and Revenue Management, interim Chief Financial Officer Canada, and Director Controlling and Operations Canada, among others. Pascal is also well-qualified academically, holding a bachelor's degree in business administration from HEC Montreal along with a CPA designation. Additionally, Saviuk informed Proactive about Valeo Pharma’s strategic efforts aimed at reducing operational costs as the company advances towards profitability. One significant move in this direction is the realignment of the company’s organizational structure. This realignment is expected to yield cost savings while enhancing the efficiency and timeliness of decision-making within the company. These changes are projected to save the company over $2 million. Contact Details Proactive +1 347-449-0879 na-editorial@proactiveinvestors.com

November 21, 2023 07:41 AM Eastern Standard Time

Video

Cyber budgets fail to meet expectations with only 1% increase on previous year in the U.S., finds S-RM

S-RM

· In 2023, the average cyber budget for large organizations grew by 3.1% YOY globally to USD 27.10 million — but only by 1% YOY in the U.S. · The increase falls below the 5% rise anticipated by Senior IT professionals and their C-suites cited in S-RM’s Cyber Security Insights Report 2023 · Nearly a third (31%) of organizations say lack of budget is a key cybersecurity challenge S-RM, a leading global corporate intelligence and cybersecurity consultancy, today published its Cyber Security Insights Report 2023, which reveals that this year’s cyber budgets for large organizations are falling short of expectations. In 2023, globally the average cyber budget grew to USD 27.10 million, up 3.1% from USD 26.30 million in 2022. In the U.S., budgets grew only by 1%. S-RM’s research shows that senior IT professionals and their C-suites had anticipated a more substantial increase of 5%, which would have seen budgets reach USD 27.60 million. The appetite for more budget comes after a year of rising operational costs – a result of wider economic turbulence – and a growing cyber threat following rapid advancements in generative AI. Cybersecurity departments want more budget to upskill employees (42%) and recruit additional skilled personnel (41%) to accommodate this rising threat. On average, cyber budgets make up a quarter (25%) of an organization's overall IT budget, marking a 1% decrease in share from 2022. This allocation varies across sectors, with Retail being the most generous (28%) and Energy & Utilities allocating the least (18%) toward tackling cyber threats. Navigating tightened purse strings Lack of budget was cited as a key challenge by nearly one third (31%) of organizations. To navigate this, cybersecurity teams have been prioritizing spend in the most ‘value for money’ areas. For the third consecutive year, investment in cyber technology topped the list, though fewer organizations highlighted technology as delivering the value commensurate with its cost in 2023 (49%) than in 2022 (58%). This dip can be attributed to a growing awareness that alongside cybersecurity technology, organizations need to invest in governance and personnel to effectively enable and manage new tech. This is a view more prevalent among IT professionals charged with implementing cyber tech solutions, with only 43% citing technology as ‘high value for money’ compared to 56% of C-suite executives. The findings reflect a misalignment of expectations between the operators of cyber technologies and those a step removed from their day-to-day applications. Organizations are adopting several other strategies to manage cybersecurity with restricted budgets: IT and security optimization - Identifying cost reduction opportunities by making existing processes more efficient to allocate budget for more critical initiatives. Future-focused investment - Investing now in security initiatives for long-term cost savings. Outsourcing - Contracting out IT and security functions to Managed Service Security Providers (MSSPs) or virtual Chief Information Security Officers (vCISOs). Paul Caron, Head of Cybersecurity, Americas at S-RM, said: “It’s reassuring that cybersecurity budgets are still rising in these challenging times, but this level of increase is simply not enough to tackle the growing cyber threat. This year’s increase has failed to meet the expectations of cyber teams and reveals that cyber security may be taking a back seat as its share of the overall IT budget declines. “Navigating ongoing skill shortages and investing in training and development of teams comes at a cost, but cyber professionals are not receiving the budget they need to deliver on these critical initiatives. Organizations will have to continue being cautious with cyber security spend, identifying those ‘value for money’ areas that will enable them to manage emerging cyber threats with tightened purse strings.” For more information, access the full 2023 Cyber Security Insights Report on S-RM's official website here: https://www.s-rminform.com/cyber-security-insights-report-2023 ENDS Notes to Editors: Methodology: The S-RM Cyber Security Insights Report 2023 follows on from our 2022 report, where we seek to understand the specific cybersecurity challenges faced by C-suite leaders and senior IT decision makers. For the 2023 report, we interviewed 602 C-Suite and senior IT professionals on the most pressing cyber challenges, cyber security incidents, and cyber budgets over the past year. For more information, access the full 2023 Cyber Security Insights Report on S-RM's official website here: https://www.s-rminform.com/cyber-security-insights-report-2023 About S-RM S-RM is a global corporate intelligence and cybersecurity consultancy with expertise in insurance, cybersecurity, and cyber response. Headquartered in London, S-RM works across 9 international offices and advises companies ranging from blue-chip corporates to large financial institutions, and beyond. To find out more about S-RM, visit https://www.s-rminform.com/ Contact Details Meir Kahtan +1 917-864-0800 mkahtan@rcn.com

November 20, 2023 02:00 PM Eastern Standard Time

News Release

Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine, TNX-1800, selected for testing in Project Next Gen, a White House initiative managed by the Department of Health and Human Services, NIH, and NIAID. The vaccine is based on a live virus platform, providing a unique approach to waking up the immune system. Live virus vaccines, like TNX-1800, offer more durable immunity that lasts a long time and can potentially block virus transmission, addressing limitations seen in mRNA vaccines. This choice of TNX-1800 is a testament to Tonix's nearly decade-long dedication to vaccine development. The technology platform can also be adapted to protect against other infectious diseases, such as monkeypox, smallpox, and tuberculosis, making it a versatile solution for future pandemics. This development highlights the significance of vaccine platforms for tackling various infectious threats. Tonix's approach promises to offer more robust, long-lasting immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. The platform's adaptability positions it as a valuable tool for future vaccine strategies. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

November 20, 2023 01:57 PM Eastern Standard Time

Video

News Release

Tonix Pharmaceuticals finish Phase 3 trial of TNX-102 SL for management of Fibromyalgia

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to shed light on the latest developments in their research efforts. The company has successfully concluded the clinical phase of a Phase 3 registration-quality study for TNX-102 SL, a drug developed for the management of fibromyalgia. This study, which is double-blind and placebo-controlled, saw the enrollment of 457 patients across various sites in the United States. Lederman conveyed to Proactive that the topline results from this study are anticipated by late December. Should the results be favorable, this trial is expected to be the conclusive well-controlled efficacy trial needed for the submission of a New Drug Application to the U.S. Food and Drug Administration. The urgency and importance of this development are underscored by the fact that an estimated 6-12 million individuals in the US are afflicted with fibromyalgia, a condition that predominantly affects women. In addition to the TNX-102 study, Lederman also discussed another significant milestone: the enrollment of the first participant in a Phase 2 study, supported by the Department of Defense, focusing on TNX-1900 for the improvement of bone health in children with autism spectrum disorder. This investigator-initiated trial represents a foray into addressing the complex needs of children with autism, potentially offering a new therapeutic avenue to enhance their quality of life. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

November 20, 2023 01:53 PM Eastern Standard Time

Video

Oxford Cannabinoid Technologies strengthens board with CMO Dr. Tim Corn

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) CEO Clarissa Sowemimo Coker and CMO Dr Tim Corn speak to Thomas Warner from Proactive after the pharmaceutical group announced the appoint of Corn to its board of directors. The move follows his appointment as Chief Medical Officer in June 2023. Sowemimo-Coker highlights the importance of having a clinician on the board of a biopharmaceutical company. The appointment follows the successful announcement of Phase I single ascending dose results in October, reflecting OCT's commitment to addressing unmet medical needs with novel therapeutic approaches. Dr. Corn cites the combination of addressing unmet medical needs and the use of a novel cannabinoid approach as key factors that have attracted him to the business. He outlines his dual focus in the role, continuing as CMO to ensure efficient clinical programs aligned with regulatory requirements and bringing a physician's perspective to the board. He suggests that his expertise in clinical development and board work positions him well to balance patient interests and financial considerations. Discussing the company's cash runway, Sowemimo-Coker says the company is funded into April 2024. She assures stakeholders that the board is actively exploring various funding options, and updates will be provided as progress unfolds. While the details remain confidential, she hints at potential updates before the end of the year. The interview showcased OCT's commitment to advancing cannabinoid-based therapies, building a strong leadership team, and maintaining transparency in financial matters. Stakeholders are eagerly anticipating further developments as OCT continues its journey towards clinical and financial success. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 20, 2023 10:24 AM Eastern Standard Time

Video

Cardio Diagnostics Establishes A New Partnership To Facilitate Global Footprint And Expansion Beyond North America With India-Based Aimil Ltd.

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Aimil Ltd., one of the companies at the forefront of India’s instrumentation industry, is a leader in introducing innovative technologies to their extensive healthcare network in India. A new Supply and Distribution Agreement with Cardio Diagnostics (NASDAQ: CDIO) has the potential to further these efforts and transform global cardiovascular healthcare in the process. As the leading cause of death in India – and the rest of the world – cardiovascular disease contributes to 282 deaths per 100,000 people in the country. This new strategic partnership aims to address this alarming prevalence by utilizing Cardio Diagnostics’ PrecisionCHD clinical test for the personalized management of coronary heart disease. In the partnership’s first phase of pre-marketing, Cardio Diagnostics will lay the groundwork for product introduction to Aimil’s healthcare network. There are plans to expand the Supply and Distribution Agreement following phase one. “Heart disease is a global problem, and Cardio Diagnostics’ expansion to India underscores our commitment to combat heart disease globally,” Cardio Diagnostics CEO Meesha Dogan Ph.D. said. “This expansion is possible because Cardio Diagnostics’ clinical tests are developed with scalability in mind with respect to operations and cost, enabling deployment across diverse healthcare landscapes worldwide, to play a transformative role in mitigating heart disease globally.” Even as Cardio Diagnostics expands to India, the company continues to grow its footprint in the U.S, including a targeted vertical expansion into innovative employers, brokers, providers and risk-bearing organizations serving Medicaid and Medicare populations Formed to improve cardiovascular disease detection by leveraging artificial intelligence-driven technology, Cardio Diagnostics seems poised for growth after partnering with Family Medicine Specialists and Vizient, Inc. After finalizing an Innovation Technology contract with Vizient, Inc. – the nation’s largest provider-driven healthcare performance improvement company – Cardio Diagnostics will have access to a customer base that it reports encompasses 60% of hospitals and 97% of academic medical centers in the United States. Similarly, Vizient provider customers will have access to Cardio Diagnostics' state-of-the-art tests at negotiated pricing, thereby increasing access to the next generation of cardiovascular disease detection technology. The contract, effective Nov. 1, signifies to Vizient hospital and health system customers a shift toward unique technology that has the potential to bring improvement to the healthcare industry. Vizient’s diverse customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers. The company transacts more than $130 billion in annual purchasing volume. This new contract with Cardio Diagnostics demonstrates Vizient’s confidence in the company’s heart attack risk assessment test, Epi+Gen CHD and coronary heart disease detection test, PrecisionCHD, which utilize a proprietary AI-driven algorithm to analyze objective epigenetic and genetic biomarkers from a patient's blood sample. Epi+Gen CHD is a pillar of a new partnership with Family Medicine Specialists (FMS), a leading Illinois primary care provider with eight locations and tens of thousands of patients across the state. With the launch of FMS’s “Heart Attack Prevention” initiative, Cardio Diagnostics’ advanced and highly sensitive blood-based epigenetic-genetic tests will be leveraged to risk stratify FMS’s patient population. FMS is implementing Epi+Gen CHD in at least 1,200 patients with CHD risk factors across its BlueCross BlueShield Medicare, Medicaid, HMO and PPO health plans. The initiative demonstrates the cost-effective benefits of early heart attack risk intervention and has the potential to help mitigate the financial and human ramifications associated with unknown heart attack risk. This benefits both patients and providers, offering significant value to health plans. By leveraging Cardio Diagnostics’ technology, clinicians at FMS will better understand their patients’ risks. Armed with more knowledge, they will be equipped with enhanced insights into the drivers of patients’ risks to aid in personalizing care. Ultimately, the initiative’s goal is to avert severe cardiac events and circumvent avoidable treatment costs, which can spiral up to hundreds of thousands of dollars for heart attacks, in addition to downstream complications like heart failure. With an eye toward the future, Cardio Diagnostics is changing the way we think about detecting and treating cardiovascular disease. These momentous partnerships underscore the company’s recent progress. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website http://www.cardiodiagnosticsinc.com/

November 20, 2023 09:00 AM Eastern Standard Time

AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new late-stage clinical and process performance qualification (PPQ) project at its Heidelberg, Germany site with Immunocore Holdings Plc (Nasdaq: IMCR). Immunocore intends to use the Heidelberg site to complete late-stage manufacturing and prepare for commercialization for IMC-F106C, Immunocore’s PRAME-targeted bispecific therapy. Under the agreement, AGC Biologics will leverage its microbial fermentation and manufacturing experience to perform bench-scale qualification and process characterization, and other required studies to support phase III manufacturing, as well as PPQ runs. Pending a successful PPQ campaign and regulatory approvals, the Immunocore project is expected to move into commercial stages at the AGC Biologics Heidelberg site. This is the next step in the partnership for this candidate between the two companies, with AGC Biologics providing early-phase support for this same project. Immunocore and AGC Biologics previously worked together on commercial manufacturing readiness for KIMMTRAK® (tebentafusp-tebn) at the CDMO’s Copenhagen site. “This is a great example of the power of the AGC Biologics network and our ability to collaborate at our global sites to support important client projects,” said Dieter Kramer, General Manager, AGC Biologics Heidelberg. “I am extremely proud of our team here in Heidelberg and the work they’ve done to support this project. We are pleased Immunocore has agreed to work with us on these next important steps in their product’s lifecycle, as our team has the late-stage and commercial expertise to deliver what is needed.” AGC Biologics runs multiple cGMP microbial fermentation lines at its Heidelberg facility. The AGC Biologics Heidelberg site has produced biologics products for 40 years and has built a track record for navigating clients through the early clinical phases and into later stages to help prepare for commercial production. In addition to fermentation, the site serves as a center of excellence for plasmid DNA (pDNA) and messenger RNA (mRNA). To learn more about AGC Biologics’ microbial system-based biologics, plasmid DNA (pDNA) and messenger RNA (mRNA) manufacturing site in Heidelberg, visit www.agcbio.com/facilities/heidelberg. For more information on the company’s Protein Biologics, pDNA, Cell Therapy, Viral Vector and mRNA drug product services go to www.agcbio.com. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com. Contact Details AGC Biologics Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com

November 20, 2023 05:08 AM Eastern Standard Time

News Release

Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301

Kiora Pharmaceuticals

Kiora Pharmaceuticals CEO Brian Strem joined Steve Darling from Proactive to share news the company's plan to broaden the clinical development of KIO-301, a treatment designed for various inherited retinal diseases. The expansion includes initiating a Phase 2 trial which will be controlled, double-masked, randomized, and will involve an ascending dose. This trial is set to include up to 20 patients suffering from Retinitis Pigmentosa (RP), who will receive doses monthly over a span of 90 days. Strem explained that this move is propelled by encouraging topline results from a Phase I/II clinical trial, which indicated that KIO-301 is a first-in-class small molecule with significant potential to improve vision for patients with RP, even those with extremely low vision or complete blindness. Moreover, Kiora Pharmaceuticals has plans to engage with the FDA in the fourth quarter of 2023. The goal of this meeting is to achieve consensus regarding the study designs, endpoints, and additional requirements necessary to conduct further studies in the United States and Europe. These studies would not only target RP but also extend to other inherited retinal diseases such as Choroideremia (CHM) and Stargardt disease. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 17, 2023 01:54 PM Eastern Standard Time

Video

1 ... 74 75 76 77 78 ... 308